Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 17.43 USD 2.65% Market Closed
Market Cap: 849.5m USD
Have any thoughts about
Uniqure NV?
Write Note

Uniqure NV
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Uniqure NV
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
Accounts Receivables
$5.3m
CAGR 3-Years
12%
CAGR 5-Years
121%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Accounts Receivables
$48.2m
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
40%
ProQR Therapeutics NV
NASDAQ:PRQR
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Accounts Receivables
$516m
CAGR 3-Years
250%
CAGR 5-Years
433%
CAGR 10-Years
89%
Merus NV
NASDAQ:MRUS
Accounts Receivables
$1.1m
CAGR 3-Years
-29%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Accounts Receivables
$1.5m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

Market Cap
849.5m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
15.99 USD
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Uniqure NV's Accounts Receivables?
Accounts Receivables
5.3m USD

Based on the financial report for Sep 30, 2024, Uniqure NV's Accounts Receivables amounts to 5.3m USD.

What is Uniqure NV's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
121%

Over the last year, the Accounts Receivables growth was 224%. The average annual Accounts Receivables growth rates for Uniqure NV have been 12% over the past three years , 121% over the past five years .

Back to Top